Beta Bionics, Inc.

A commercial-stage medical device company is engaged in the design, development, and commercialization of innovative solutions aimed at improving the health and quality of life of insulin-requiring people with diabetes (PWD). By utilizing advanced adaptive closed-loop algorithms, the company seeks to simplify and enhance the treatment of diabetes. Diabetes is a serious, chronic, and often lifelong condition with no known cure, characterized by prolonged periods of elevated blood glucose levels, or hyperglycemia, resulting from the body's inability to produce or effectively utilize insulin. Managing diabetes requires PWD to adhere to a rigorous daily insulin regimen, as prolonged hyperglycemia can lead to severe and potentially life-threatening cardiovascular, metabolic, and nervous system complications.

Despite decades of advancements in diabetes care, a significant unmet need remains, as the majority of PWD still struggle to manage their condition effectively. The company’s product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to use adaptive closed-loop algorithms that autonomously determine every insulin dose without requiring users to count carbohydrate intake. This innovation represents a significant advancement over existing insulin delivery technologies by offering an improved combination of glycemic control and a vastly simplified user experience for both individuals with diabetes and their caregivers.